232TiPA multicentre, international neoadjuvant, double-blind, randomized phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib (CDK 4/6 inhibitor) in patients with operable luminal breast cancer responding to fulvestrant (SAFIA study)
Nabholtz, J-M, Al Saleh, K, Bounedjar, A, Abdel-Razeq, H, Errihani, H, Saadeddin, A, Al Foheidi, M, Ghosn, M, El Zawahry, H, Kandil, A, Abdel-Aziz, N, Dabouz, F, Kullab, SVolume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy270.227
Date:
October, 2018
File:
PDF, 82 KB
english, 2018
File converter
More search results
More benefits 
